GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
6.7k
c/trialwatch·posted 2 years ago by u/rohan_steiner

[PSA] write the concentration on the vial. that is the whole post.

Trial Data Receipts ×7 Long Haul ×2 Clean Column ×2

write the concentration on the vial. that is the whole post. Two minutes of reading now saves an argument later.

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Screenshot none of this. Read the whole thread, including the parts where I am told I am wrong.

25,263 up / 18,534 down58% upvoted40 commentsid 4yctap18 Mar 2024

40 comments

16 in this archive, depth 4

best — the order this archive was captured in

u/milan_mensah501 points·2 years ago

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

replysharereportpermalink
u/blunt_coldbox_notes0 points·2 years ago

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

replysharereportpermalink
u/renal_outcomes_rMOD190 points·2 years ago

Added the trial identifier to the title so this thread is findable in two years.

replysharereportpermalink
u/rt_shift_reggie153 points·2 years ago

Read a press release and the publication three months apart. The hedging in the second one was substantial.

replysharereportpermalink
u/sofia_ferreira86 points·2 years ago

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

replysharereportpermalink
u/piotr_bruun64 points·2 years ago

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/oskar_ibarra15 points·2 years ago·edited

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

replysharereportpermalink
u/blunt_coldbox_notes6 points·2 years ago

intention to treat versus completers changes the number substantially

replysharereportpermalink
u/tb500_tangent0 points·2 years ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/ines_castellanos51 points·2 years ago

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/milan_villalobos18 points·2 years ago

That is a relative risk reduction.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

replysharereportpermalink
u/receipts_or_nothingvetting14 points·2 years ago

trial populations get support that nobody on this board gets

replysharereportpermalink
u/pancreatitis_scare4 points·2 years ago

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

replysharereportpermalink
u/yusuf_ramos6 points·2 years ago

read the endpoint before you read the headline

replysharereportpermalink
u/hsa_math37 points·2 years ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/yusuf_ramos52 points·2 years ago

a press release is not a publication

replysharereportpermalink
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.